BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 20110413)

  • 1. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.
    Ciarimboli G; Deuster D; Knief A; Sperling M; Holtkamp M; Edemir B; Pavenstädt H; Lanvers-Kaminsky C; am Zehnhoff-Dinnesen A; Schinkel AH; Koepsell H; Jürgens H; Schlatter E
    Am J Pathol; 2010 Mar; 176(3):1169-80. PubMed ID: 20110413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.
    Filipski KK; Mathijssen RH; Mikkelsen TS; Schinkel AH; Sparreboom A
    Clin Pharmacol Ther; 2009 Oct; 86(4):396-402. PubMed ID: 19625999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity.
    Guo D; Yang H; Li Q; Bae HJ; Obianom O; Zeng S; Su T; Polli JE; Shu Y
    Pharm Res; 2018 Sep; 35(11):204. PubMed ID: 30191328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs).
    Li Q; Guo D; Dong Z; Zhang W; Zhang L; Huang SM; Polli JE; Shu Y
    Toxicol Appl Pharmacol; 2013 Nov; 273(1):100-9. PubMed ID: 24001450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Membrane transporters as mediators of cisplatin side-effects.
    Ciarimboli G
    Anticancer Res; 2014 Jan; 34(1):547-50. PubMed ID: 24403515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase.
    Franke RM; Kosloske AM; Lancaster CS; Filipski KK; Hu C; Zolk O; Mathijssen RH; Sparreboom A
    Clin Cancer Res; 2010 Aug; 16(16):4198-206. PubMed ID: 20601443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MATE1 expression in the cochlea and its potential involvement in cisplatin cellular uptake and ototoxicity.
    Waissbluth S; Martínez AD; Figueroa-Cares C; Sánchez HA; Maass JC
    Acta Otolaryngol; 2023 Mar; 143(3):242-249. PubMed ID: 36943799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Saving ears and kidneys from cisplatin.
    Wensing KU; Ciarimboli G
    Anticancer Res; 2013 Oct; 33(10):4183-8. PubMed ID: 24122981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPAR-α Deletion Attenuates Cisplatin Nephrotoxicity by Modulating Renal Organic Transporters MATE-1 and OCT-2.
    Freitas-Lima LC; Budu A; Arruda AC; Perilhão MS; Barrera-Chimal J; Araujo RC; Estrela GR
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33049997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wedelolactone protects against cisplatin-induced nephrotoxicity in mice via inhibition of organic cation transporter 2.
    Wang G; Bi Y; Xiong H; Bo T; Han L; Zhou L; Zhang C; Zhang Y
    Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S447-S459. PubMed ID: 34592875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity.
    Pabla N; Murphy RF; Liu K; Dong Z
    Am J Physiol Renal Physiol; 2009 Mar; 296(3):F505-11. PubMed ID: 19144690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the nephrotoxicity in the mouse during repeated cisplatin (CDDP) treatments.
    Yajima Y; Kawaguchi M; Yoshikawa M; Okubo M; Tsukagoshi E; Sato K; Katakura A
    J Pharmacol Sci; 2017 Jun; 134(2):108-115. PubMed ID: 28648300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin-induced renal injury is independently mediated by OCT2 and p53.
    Sprowl JA; Lancaster CS; Pabla N; Hermann E; Kosloske AM; Gibson AA; Li L; Zeeh D; Schlatter E; Janke LJ; Ciarimboli G; Sparreboom A
    Clin Cancer Res; 2014 Aug; 20(15):4026-35. PubMed ID: 24916697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity.
    Nakamura T; Yonezawa A; Hashimoto S; Katsura T; Inui K
    Biochem Pharmacol; 2010 Dec; 80(11):1762-7. PubMed ID: 20813096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-tetrahydropalmatine attenuates cisplatin-induced nephrotoxicity via selective inhibition of organic cation transporter 2 without impairing its antitumor efficacy.
    Li C; Li L; Yi Y; Wang W; Yuan J; Tan F; Fang D; Zeng S; Zhou H; Jiang H
    Biochem Pharmacol; 2020 Jul; 177():114021. PubMed ID: 32389634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant lansoprazole ameliorates cisplatin-induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats.
    Hiramatsu SI; Ikemura K; Fujisawa Y; Iwamoto T; Okuda M
    Biopharm Drug Dispos; 2020 Jun; 41(6):239-247. PubMed ID: 32473602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical localization of OCT2 in the cochlea of various species.
    Hellberg V; Gahm C; Liu W; Ehrsson H; Rask-Andersen H; Laurell G
    Laryngoscope; 2015 Sep; 125(9):E320-5. PubMed ID: 25892279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Platinum agent-induced nephrotoxicity via organic cation transport system].
    Yonezawa A
    Yakugaku Zasshi; 2012; 132(11):1281-5. PubMed ID: 23123720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrative approach to cisplatin chronic toxicities in mice reveals importance of organic cation-transporter-dependent protein networks for renoprotection.
    Hucke A; Rinschen MM; Bauer OB; Sperling M; Karst U; Köppen C; Sommer K; Schröter R; Ceresa C; Chiorazzi A; Canta A; Semperboni S; Marmiroli P; Cavaletti G; Schlatt S; Schlatter E; Pavenstädt H; Heitplatz B; Van Marck V; Sparreboom A; Barz V; Knief A; Deuster D; Zehnhoff-Dinnesen AA; Ciarimboli G
    Arch Toxicol; 2019 Oct; 93(10):2835-2848. PubMed ID: 31493026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin.
    Fox E; Levin K; Zhu Y; Segers B; Balamuth N; Womer R; Bagatell R; Balis F
    Oncologist; 2018 Jul; 23(7):762-e79. PubMed ID: 29445029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.